Literature DB >> 15517848

Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders.

Sanjay Gupta1, Prakash Masand.   

Abstract

The discovery of antipsychotic medications has revolutionized the treatment of schizophrenia and other psychotic disorders. However, side effects such as extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), electrocardiogram (ECG) changes, weight gain, and metabolic disturbances indicate the continued need to develop new agents. The introduction of atypical drugs such as clozapine, risperidone, olanzapine, quetiapine, and ziprasidone has widened our choices. This article provides an overview of the pharmacology, efficacy, and techniques for the clinical use of aripiprazole, a novel agent with a unique pharmacological profile.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517848     DOI: 10.1080/10401230490487007

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  4 in total

1.  Two instances of improvement in tardive dyskinesia after administration of aripiprazole in a single patient.

Authors:  Chih-Lun Chen; Han-Wei Chou
Journal:  Prim Care Companion CNS Disord       Date:  2012

2.  Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats.

Authors:  Ming Li; Radek Budin; Alison S Fleming; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

3.  Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.

Authors:  Konstantinos N Fountoulakis; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2009-07-27       Impact factor: 3.455

4.  Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats.

Authors:  Dalia A Nawwar; Hala F Zaki; Rabab H Sayed
Journal:  Inflammopharmacology       Date:  2022-07-25       Impact factor: 5.093

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.